Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04403997
Other study ID # NBICromo
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2019
Est. completion date February 25, 2022

Study information

Verified date July 2021
Source Hospital Universitario La Paz
Contact Eduardo Martín Arranz, PhD
Phone +34912071350
Email emarranz@salud.madrid.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to compare the detection of neoplastic lesions between chromoendoscopy and NBI


Description:

Single-blind (patient) randomized study to compare detection of neoplastic lesions between chromoendoscopy and NBI. Patients with Inflammatory Bowel Disease who are to undergo chromoendoscopy according to usual clinical criteria will be included. The endoscopic procedure is similar to the one usually performed. All patients will undergo colonoscopy according to the usual procedure, with Olympus HQ190 series endoscopes, with the same bowel preparation. During intubation, the faecal remains will be thoroughly washed. Patients will be randomly assigned to one of the two techniques: Chromoendoscopy with 0.1% methylene blue or New generation NBI with Near focus. Biopsies will be taken of all those lesions detected, instead of random biopsies.


Recruitment information / eligibility

Status Recruiting
Enrollment 175
Est. completion date February 25, 2022
Est. primary completion date December 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Patients with an established diagnosis of Inflammatory Bowel Disease with indication to undergo chromoendoscopy Exclusion Criteria: - Patients who are not trained to understand the nature of the study, the procedures to be followed or are not able to sign an informed consent - Known allergy or intolerance to methylene blue - Pregnant or lactating women - Personal history of colorectal cancer - Ulcerative colitis active more than 20 cm from the anal verge - Patients with known G6PD deficiency - Severe kidney failure

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Chromoendoscopy
Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.

Locations

Country Name City State
Spain Hospital Universitario La Paz Madrid

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitario La Paz

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lesions detected Total number of IBD dysplastic lesions detected by the use of NBI virtual chromoendoscopy versus conventional chromoendoscopy Baseline
Secondary Detection rate of dysplastic lesions Number of patients with at least one dysplastic lesion Baseline
Secondary Non-dysplastic lesions Assess the number of non-dysplastic lesions detected with both methods Baseline
Secondary Ratio of neoplastic lesions/total lesions Compare the ratio of neoplastic lesions/total lesions between both groups Baseline
Secondary Total endoscopy time The total endoscopy time is counted from the introduction of the endoscope in the patient until its complete removal Baseline
Secondary Removal time Withdrawal time is counted from the time the cecum is reached to the completion of the test, including time spent on staining, biopsy or polypectomy Baseline
Secondary Near Focus ability Assess Near Focus ability to optically differentiate dysplastic from non-dysplastic lesions Baseline
Secondary Number of biopsies Number of biopsies taken in the different groups Baseline
See also
  Status Clinical Trial Phase
Completed NCT03824418 - The Clinical Value of Chromoendoscopy as Surveillance Strategy for Dysplasia Detection in Ulcerative Colitis
Recruiting NCT02631798 - Chromocolonoscopy With Food-grade Dyes N/A